Popović V, Micić D, Nesović M, Djordjević P, Mićić J, Djurić D S
Exp Clin Endocrinol. 1985 Jun;85(3):351-7. doi: 10.1055/s-0029-1210461.
Blood glucose, plasma GH, insulin and glucagon levels during OGTT before and after treatment with bromocriptine (20 - 40 mg daily 3 - 18 months) were studied in 12 nondiabetic acromegalics (NA) and 6 diabetic acromegalics (DA) not treated previously. There was no significant change in blood glucose levels before and after treatment in NA while blood glucose levels fell significantly in DA after treatment. Mean basal GH levels and after OGTT decreased significantly in NA group, while only in the 120 min of OGTT in DA group. There was no significant change in mean basal or glucose stimulated plasma insulin or glucagon levels before and after treatment in both non-diabetic and diabetic acromegalics. Normal glucagon levels in diabetic acromegalics prior to treatment is considered as relative hyperglucagonaemia which disappeared after treatment. We did not show that glucagon suppressibility after OGTT was reestablished after treatment with bromocriptine in non-diabetic and diabetic acromegalics. Other factors than changes in hormones should be considered as a cause of restored glucose tolerance.
对12例未经治疗的非糖尿病性肢端肥大症患者（NA）和6例糖尿病性肢端肥大症患者（DA）进行了研究，观察了他们在服用溴隐亭（每日20 - 40mg，疗程3 - 18个月）前后口服葡萄糖耐量试验（OGTT）期间的血糖、血浆生长激素（GH）、胰岛素和胰高血糖素水平。NA组治疗前后血糖水平无显著变化，而DA组治疗后血糖水平显著下降。NA组基础GH水平及OGTT后均显著降低，而DA组仅在OGTT 120分钟时降低。非糖尿病和糖尿病肢端肥大症患者治疗前后基础或葡萄糖刺激的血浆胰岛素或胰高血糖素水平均无显著变化。糖尿病肢端肥大症患者治疗前正常的胰高血糖素水平被认为是相对高胰高血糖素血症，治疗后消失。我们并未表明在非糖尿病和糖尿病肢端肥大症患者中，服用溴隐亭治疗后OGTT后胰高血糖素的抑制能力得以恢复。除激素变化外，其他因素也应被视为葡萄糖耐量恢复的原因。
